Small Airways DiseasesVapingVaping Related DisorderVaping TeensVaping Behavior
Study summary
Vaping is increasingly popular with both adolescent and adult Canadians, but the long-term health impacts remain unknown. We believe that the tools we currently have to detect lung disease in people who vape may be insufficient and propose new ways to find lung injuries that may impact them over the course of their lives. These include exercise testing, new imaging techniques, and new breathing tests that will demonstrate how vaping may harm their lungs. We will use these tools in both adolescent and adult Canadians to give Canadians who vape important information on the consequences of vaping.
Eligibility
Sex
ALL
Min age
12 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
Adolescent arm:
* Aged ≥12 and \<19 years old
* Either 1) use neither combustible cigarettes nor e-cigarettes or 2) use e-cigarettes exclusively
Adult arm:
* Aged ≥19 years old
* Fall into one of the following categories: 1) use neither combustible cigarettes nor e-cigarettes; 2) use combustible cigarettes exclusively, never using e-cigarettes; 3) use e-cigarettes exclusively, never using combustible cigarettes; or 4) use both combustible cigarettes and e-cigarettes currently
Exclusion Criteria:
Adolescent arm:
* Contraindication to pulmonary function testing and cardiopulmonary exercise testing
* Have smoked combustible cannabis within the last month and/or have a combustible cannabis smoking history of \>1 joint-year
* Have smoked combustible cigarettes within the last 6 months
* Have a physician-diagnosed chronic lung disease (such as asthma, cystic fibrosis, or bronchopulmonary dysplasia)
* Inability to provide written informed consent
Adult arm:
* Contraindication to pulmonary function testing and cardiopulmonary exercise testing
* Have smoked combustible cannabis within the last month and/or have a combustible cannabis smoking history of \>1 joint-year
* Currently undergoing treatment for lung cancer
* Inability to provide written informed consent
No limitations will be placed on the type of e-liquids used by participants; e.g., e-cigarette users of nicotine, tetrahydrocannabinol, and cannabidiol will be all enrolled.
Primary outcome measure(s)
Composite Measure of Small Airways Dysfunction — From enrollment (Baseline) to the end of study participation (36 Months). Participants meeting at least one of the following criteria will be considered to have small airways dysfunction:
For adolescent participants, these measures will include 1) a change in resistance from 5-20 Hz (R5-R20) \>upper limit of normal (ULN) on oscillometry or 2) peak oxygen consumption (VO2)\<lower limit of normal (LLN) plus a ventilatory response or minute ventilation/carbon dioxide production (VE/VCO2) nadir \>ULN. For adult participants, these measures will include 1) R5-R20 \>ULN, 2) disease probability measure functional small airways disease \>10% on chest CT, or 3) peak VO2\<84% predicted plus a VE/VCO2 nadir \>ULN. The proportion of participants meeting at least one of the criteria for small airways dysfunction at any time point will be compared between the vaping and control groups using Chi-square tests. Multivariable logistic regressions will be used to adjust for possible covariates, such as age, sex, and their interaction with vaping/smoking groups.
Trial sites (8)
Facility
City
Region
Status
University of Alberta (Clinical Sciences Building)
Edmonton
Alberta
Recruiting
BC Cancer Agency
Vancouver
British Columbia
Recruiting
BC Children's Hospital Research Institute
Vancouver
British Columbia
Recruiting
St. Paul's Hospital
Vancouver
British Columbia
Recruiting
McMaster University (Research Institute of St. Joe's Hamilton)
Hamilton
Ontario
Not Yet Recruiting
University of Ottawa (The Ottawa Hospital General Campus)
Ottawa
Ontario
Recruiting
University of Toronto (The Hospital for Sick Children)
Toronto
Ontario
Not Yet Recruiting
Université de Sherbrooke
Sherbrooke
Quebec
Not Yet Recruiting
More University of British Columbia trials in Canada
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.